A breed of pigs called Wisconsin Miniature Swine created by a team of UWMadison scientists will help researchers better model and understand human diseases. Photo: Jeff Miller

Cells from miniature pigs are paving the way for improved stem cell therapies.

A team led by University of WisconsinMadison Stem Cell & Regenerative Medicine Center researcher Wan-Ju Li offers an improved way to create a particularly valuable type of stem cell in pigs a cell that could speed the way to treatments that restore damaged tissues for conditions from osteoarthritis to heart disease in human patients.

In a study published in Scientific Reports, Lis team also provides insights into the reprogramming process that turns cells from one part of the body into pluripotent stem cells, a type of building block cell that can transform into any type of tissue. These new insights will help researchers study treatments for a wide range of diseases.

The researchers turned to pigs, a well-established animal model for potential human treatments, because translating research to improve human health is deeply important to Li, a professor of Orthopedics and Rehabilitation and Biomedical Engineering. He has spent much of his career studying cartilage and bone regeneration to develop innovative therapies to help people.

Li and members of his Musculoskeletal Biology and Regenerative Medicine Laboratory obtained skin cells from the ears of three different breeds of miniature pigs Wisconsin miniature swine, Yucatan miniature swine and Gttingen minipigs.

University of WisconsinMadison Stem Cell & Regenerative Medicine Center researcher Wan-Ju Li (left) shows a collagen fiber sample to Gwen Plunkett and Karen Plunkett. Funding from the Plunkett Family Foundation has contributed to research on cartilage repair therapies in UWMadisons Musculoskeletal Research Program.

The researchers reprogrammed the cells to create induced pluripotent stem cells and demonstrated that they have the capacity to become different types of tissue cells. Pluripotent stem cells are the bodys master cells, and they are invaluable to medicine since they can be used for the regeneration or repair of damaged tissues.

Findings of this study suggest that the miniature pig is a promising animal model for pre-clinical research. The team plans to use the established pig model to reproduce their recent findings of cartilage regeneration in rats as reported in Science Advances. Regenerating cartilage in animals even more alike to humans moves science one step closer to helping patients experiencing joint diseases such as osteoarthritis.

In successfully developing induced pluripotent stem cells from three different breeds of minipigs, we learned we can take somatic skin cells from these pigs that we programmed ourselves and then inject them back into the same animal to repair cartilage defects, says Li. Or we can create induced pluripotent stem cells from the skin cell that carried the gene causing cartilage diseases such as chondrodysplasia and put that into the culture dish and use that as a disease model to study disease formation.

Li says the approach can be applied to regenerative therapies targeting any organ or tissue.

The team also found that a particular protein complex involved in managing the way genes are expressed, and tied to cellular growth and survival, could influence how efficiently induced pluripotent stem cells are generated. While we successfully created induced pluripotent stem cells from the three different strains of pig, we noticed that some pigs had a higher reprogramming efficiency, says Li. So, the second part of our findings, which is significant in biology, is understanding how these differences occur and why.

These findings, he says, may directly translate to understanding differences in the effectiveness of induced pluripotent stem cell generation between individual people one study has shown cellular reprogramming efficiency varying by age and ancestry and lead to better tailored therapies.

I want to make sure that our findings in stem cell research can be used to help people, says Li. I just feel this internal drive to study this area and I feel good knowing this model carries significant weight in terms of its potential for translational stem cell research and the development of therapeutic treatments.

Interest in moving these treatments forward has grown, and while the study was funded in part by the National Institutes of Health, Li also received support from the Milwaukee-based Plunkett Family Foundation through their donation to the UW Stem Cell & Regenerative Medicine Center. After hearing of Lis research, Gwen Plunkett and her daughter Karen visited Lis lab in 2019 to learn more. They were inspired to support research into stem cells for cartilage regeneration.

Innovation in medicine sparks critical change, for the world and the survival of our species, and the Plunkett Family mission is to be a catalyst in stem cell and regenerative medicine research, says Karen Plunkett.

The donation was profoundly impactful, says Li, allowed him to further his goal of using stem cells to help patients living with osteoarthritis and other joint diseases many of whom write his lab regularly in hope of finding a clinical trial opportunity.

I have to keep saying, Wait for another two, three years, maybe well be ready for a clinical trial, Li says. But for me, its time to move on and really do our larger animal studies to fulfill our promise. At least that way, I can fill the gap between the lab and clinical trials as the larger animals must be studied before you go into a clinical trial.

This research was supported by grants from the National Institutes of Health (R01 AR064803), the Plunkett Family Foundation and UW Carbon Cancer Center.

Originally posted here:
Creating stem cells from minipigs offers promise for improved treatments - University of Wisconsin-Madison

Calgary, Alberta--(Newsfile Corp. - September 14, 2022) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) ("Hemostemix" or the "Company") is pleased to announce the appointment of Dr. Renzo Cecere, MD, FRCSC, to its Scientific Advisory Board.

Dr. Cecere is the McGill University Chief of Cardiac Surgery, Surgical Director of the Heart Failure and Heart Transplantation Program, and Director of the Mechanical Circulatory Support Program. He is also Associate Member of the McGill University Department of Mechanical Engineering, and a Director and Principal Investigator of the Research Institute of the MUHC Myocardial Regeneration Laboratory.

For over a decade, Dr. Cecere's lab has been investigating novel methods to strengthen the stem-cell induced regeneration of infarcted heart tissue. Dr. Cecere has utilized placenta-derived stem cells and investigated their regenerative potential in different animal models of myocardial infarction ("MI"). More recently, Dr. Cecere's lab is actively involved in a project to create a platform to generate patient-specific cardiomyocytes from the blood of patients with heart failure. In Dr. Cecere's recent project (under review, Journal of Tissue Engineering and Regenerative Medicine), the team encapsulated placenta derived stem cells in a hydrogel scaffold and implanted it in a rat MI model. The stem cell/scaffold composite enhanced several parameters of cardiac function, including ejection fraction and fractional shortening, while also reducing fibrosis and increasing angiogenesis. In fact, Dr. Cecere's lab recently published a systematic review and meta-analysis that demonstrated that stem cells combined with bioactive scaffolds provide enhanced tissue regeneration in animal models of MI, compared to stem cells injected alone. This study paves the way for future research and clinical trials, supporting the use of ACP-01-based bioactive scaffolds to improve the stem cell-induced repair after a MI.

"I have worked in the field of heart-based stem cell science for more than a decade, and I find ACP-01's unique properties, safety profile and statistically significant preliminary intramyocardial efficacy results to be very promising" said Dr. Cecere. I look forward to collaborating with management to create the best product to repair hearts before an infarct or following an infarct, and designing a clinical trial of ACP-01 that proves its efficacy" said Dr. Cecere.

"Hemostemix is delighted to welcome Dr. Cecere to our team. His appointment to the SAB is the first of many areas of collaboration. As one of Canada's most well-regarded stem cell focused heart transplant surgeons, Dr. Cecere and his team enable Hemostemix to fast-track product development and clinical trials. We very much look forward to his counsel and his teams' collaboration to trial ACP-01 based bioactive scaffolds to improve stem cell-induced repair of the heart," stated Thomas Smeenk, CEO.

ABOUT HEMOSTEMIX

Hemostemix is an autologous stem cell therapy company, founded in 2003. A winner of the World Economic Forum Technology Pioneer Award, the Company has developed, patented, and is scaling a patient's blood-based stem cell therapeutics platform that includes angiogenic cell precursors, neuronal cell precursor and cardiomyocyte cell precursors. Seven studies including 260 ACP-01 recipients define its safety and efficacy profile as a treatment for heart diseases such as Dilated and Ischemic Cardiomyopathy, Angina, and diseases of Ischemia such as Critical Limb Ischemia. The Company owns 91 patents across five patent families. For more information, please visit http://www.hemostemix.com.

For further information, please contact: Thomas Smeenk, President, CEO & Co-FounderEM: tsmeenk@hemostemix.com PH: 905-580-4170

Neither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined under the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-Looking Information: This news release contains "forward-looking information" within the meaning of applicable Canadian securities legislation. All statements, other than statements of historical fact, included herein are forward-looking information. In particular, this news release contains forward-looking information in relation to: the lead product ACP-01, future studies of ACP-01 in bioactive scaffolds to improve the stem cell-induced repair after an infarct, the company's Clinical Trial results, and the results of the retrospective study of ischemic and dilated cardiomyopathy, and the commercialization of ACP-01. There can be no assurance that such forward-looking information will prove to be accurate. Actual results and future events could differ materially from those anticipated in such forward-looking information. This forward-looking information reflects Hemostemix's current beliefs and is based on information currently available to Hemostemix and on assumptions Hemostemix believes are reasonable. These assumptions include, but are not limited to: the underlying value of Hemostemix and its Common Shares; the successful resolution of the litigation that Hemostemix is pursuing or defending (the "Litigation"); the results of ACP-01 research, trials, studies and analyses, including the analysis being equivalent to or better than previous research, trials or studies; the receipt of all required regulatory approvals for research, trials or studies; the level of activity, market acceptance and market trends in the healthcare sector; the economy generally; consumer interest in Hemostemix's services and products; competition and Hemostemix's competitive advantages; and Hemostemix obtaining satisfactory financing to fund Hemostemix's operations including any research, trials or studies, and any Litigation. Forward-looking information is Subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of Hemostemix to be materially different from those expressed or implied by such forward-looking information. Such risks and other factors may include, but are not limited to: the ability of Hemostemix to complete clinical trials, complete a satisfactory analyses and file the results of such analyses to gain regulatory approval of a phase II or phase III clinical trial of ACP-01; potential litigation Hemostemis mayface; general business, economic, competitive, political and social uncertainties; general capital market conditions and market prices for securities; delay or failure to receive board or regulatory approvals; the actual results of future operations including the actual results of future research, trials or studies; competition; changes in legislation affecting Hemostemix; the timing and availability of external financing on acceptable terms; long-term capital requirements and future developments in Hemostemix's markets and the markets in which it expects to compete; lack of qualified, skilled labour or loss of key individuals; and risks related to the COVID-19 pandemic including various recommendations, orders and measures of governmental authorities to try to limit the pandemic, including travel restrictions, border closures, non-essential business closures service disruptions, quarantines, self-isolations, shelters-in-place and social distancing, disruptions to markets, disruptions to economic activity and financings, disruptions to supply chains and sales channels, and a deterioration of general economic conditions including a possible national or global recession or depression;the potential impact that the COVID-19 pandemic may have on Hemostemix which may include a decreased demand for the services that Hemostemix offers; and a deterioration of financial markets that could limit Hemostemix's ability to obtain external financing. A description of additional risk factors that may cause actual results to differ materially from forward-looking information can be found in Hemostemix's disclosure documents on the SEDAR website at http://www.sedar.com. Although Hemostemix has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. Readers are cautioned that the foregoing list of factors is not exhaustive. Readers are further cautioned not to place undue reliance on forward-looking information as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Forward-looking information contained in this news release is expressly qualified by this cautionary statement. The forward-looking information contained in this news release represents the expectations of Hemostemix as of the date of this news release and, accordingly, it is Subject to change after such date. However, Hemostemix expressly disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as expressly required by applicable securities law.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/137137

View original post here:
Hemostemix Announces the Appointment of Dr. Renzo Cecere, MD, FRCSC to Its Scientific Advisory Board - Yahoo Finance

September 15, 2022 The intestine is very susceptible and is affected by the harsh conditions caused by DNA-altering agents, such asradiationand chemotherapy, during cancer treatment. For example, many patients with tumors in the gastrointestinal cavity receive radiotherapy, a treatment that often also damages the healthy intestine and affects its regenerative capacity. It is therefore very important to understand how intestinal epithelial regeneration occurs. The cellular and molecular mechanisms involved in this key process are not yet fully understood.

Researchers at theSpanish National Cancer Research Centre(CNIO) have now discovered one of the cellular and molecular mechanisms essential for the regeneration of the intestinal epithelium. This finding lays the foundations for stimulating this process if it fails, and for protecting it againstdamage caused by radiotherapyand chemotherapy.

According to the study, what prompts intestinal stem cells to regenerate the mucosa depends on the communication between different cell types in the epithelial tissue. The researchers have also found a way to intervene in this communication, and thereby, boost intestinal regeneration.

The paperis published this week inJournal of Experimental Medicine. The research is led by the head of the CNIO's Growth Factors, Nutrients and Cancer Group, Nabil Djouder, and Almudena Chaves-Prez and Karla Santos-de-Frutos are first authors.

The group has spent years researching how to improve the regeneration of various organsparticularly the liver and intestinal mucosaand thus mitigate the effects of radiotherapy. Their findings during this period have been published in high-impact journals.

"Regeneration of the intestinal epithelium is very important in the proper functioning of the intestine," explains Djouder. "Until now, we knew that it was driven by powerful mitogenic factorsproteinsthat stimulate the proliferation of intestinal stem cells, but we didn't know how these factors were regulated."

This new study suggests thatunexpectedly for the researchers it is the progenitor cells involved in regenerating the epithelial mucosa that modulate the production of mitogenic factors. The process is as follows: when severe damage occurs, injury to the progenitor cells leads to tissue inflammation; this in turn slows down the production of mitogenic factors and thus the proliferation of stem cells and the subsequent regeneration of the mucous membrane.

"For us, this communication between at least four different cell types is new: progenitor cells, which differentiate to form the epithelial mucosa; cells that secrete mitogenic factors; inflammatory cells; and intestinal stem cells themselves," says Djouder. "This communication must be very well controlled, so that the tissue responds appropriately to aggressions."

"That progenitor cells communicate with inflammatory cells and coordinate the proliferation rate of intestinal stem cells is fascinating," he adds.

Djouder places particular emphasis on the new role that progenitor cells have been found to play: "Our study suggests that progenitor cells are not mere bystanders in the process of epithelial regeneration, but play an active and important role in the decisions that intestinal stem cells make in regeneration. Progenitor cells tell intestinal stem cells when and how to divide, and thus control their self-regeneration."

"This study has allowed us to better understand cell cooperation in order to find new ways to reduce adverse effects in traditional cancer treatments," say Chaves-Prez and Santos-de-Frutos, lead authors of the paper.

The group has also confirmed findings observed in previous work, namely that c-MYC oncogene plays a key role in regeneration. Due to radiation damage and the increase of c-MYC in progenitor cells, inflammation in the intestine increases and mitogenic protein levels are reduced; however, by removing or inhibiting c-MYC, the process is reversed: inflammation is reduced, mitogenic factors increase and intestinal regeneration during severe damage improves.

"Our data show an unexpected role for progenitor cells in the control of inflammatory signalling and mitogenic factor production, essential for maintaining intestinal stem cell proliferation and tissue regeneration," the authors write.

The finding, they say, breaks new ground in research into how to counteract the side effects of radiotherapy in patients with gastrointestinal cancer.

The work has been funded by the Ministry of Science and Innovation, the Carlos III Health Institute, the European Regional Development Fund, the Community of Madrid and the Spanish Association Against Cancer.

For more information:https://www.cnio.es/en/

Read the original here:
Discovered Key Mechanisms to Improve Intestinal Regeneration and Alleviate the Side Effects of Radiotherapy - Imaging Technology News

News Release

Wednesday, September 14, 2022

NIH study shows the role of transcription factors in facilitating cell regeneration.

National Institutes of Health researchers have discovered a specific network of proteins that is necessary to restore hearing in zebrafish through cell regeneration. The study, led by investigators at the National Human Genome Research Institute (NHGRI), may inform the development of treatments for hearing loss in humans. The findings were published in Cell Genomics.

Although hair cell loss cannot be replaced in humans, many animals, including zebrafish, can restore hearing after injury through the regeneration of hair cells. The regenerative properties of zebrafish hair cells prompted researchers to use this animal to understand some fundamental properties of regeneration.

Hearing loss affects around 37.5 million Americans, and most cases come from the loss of hearing receptors known as hair cells in the inner ear. Bristles that stick out of these microscopic hair cells move and bend when sound travels into our ears, resulting in electric signals sent through nerves and into our brains that allow us to process sound.

Humans and zebrafish are visually quite different, but at a genomic level, they share more than 70% of their genes. This genomic similarity offers the potential for researchers to understand the biology of cell regeneration in zebrafish before translating the findings to humans.

Erin Jimenez, Ph.D., a postdoctoral fellow in the laboratory of Shawn Burgess, Ph.D., senior investigator in the National Human Genome Research Institutes (NHGRI) Translational and Functional Genomics Branch, led the study in collaboration with researchers Ivan Ovcharenko, Ph.D., and Wei Song, Ph.D., at the National Library of Medicines National Center for Biotechnology Information.

Humans and other mammals are born with a set number of hair cells that are slowly lost through aging and trauma. However some animals, such as zebrafish, can regenerate hair cells and recover hearing after injury, said Burgess. How and why regeneration happens in these animals remain a mystery that many scientists would like to unravel.

Using a combination of genomic techniques and computational-based machine learning, Jimenez and her collaborators found that hair cell regeneration in zebrafish relied on a network of proteins that can switch genes on and off, known as transcription factors. To properly identify which transcription factors were at play, the researchers first had to look at the enhancer sequences within the zebrafish genome.

If transcription factors are thought of as the keys that turn a car on and off, enhancer sequences are the cars ignition switch. Both parts need to interact to make a car run, just like how transcription factors need to bind to specific enhancer sequences to express a gene.

The researchers used new genomic techniques called single-cell RNA sequencing and single-cell assay for transposase-accessible chromatin using sequencing to identify the enhancer sequences and their corresponding transcription factors that play a role in hair cell regeneration.

Our study identified two families of transcription factors that work together to activate hair cell regeneration in zebrafish, called Sox and Six transcription factors, said Jimenez.

First, the Sox transcription factors initiate the regeneration response in surrounding cells, called support cells. Next, the Sox and Six transcription factors cooperate to turn those support cells into hair cells.

When hair cells die in zebrafish, nearby support cells start replicating. These support cells are like stem cells because of their ability to become other cell types. Researchers had identified some of the factors that convert support cells into hair cells, but what was not understood is how and where the genes encoding those factors turn on and are coordinated with other unknown factors.

We have identified a unique combination of transcription factors that trigger regeneration in zebrafish. Further down the line, this group of zebrafish transcription factors might become a biological target that may lead to the development of novel therapy to treat hearing loss in humans, Jimenez said.

The National Human Genome Research Institute (NHGRI) is one of the 27 institutes and centers at the NIH, an agency of the Department of Health and Human Services. The NHGRI Division of Intramural Research develops and implements technology to understand, diagnose and treat genomic and genetic diseases. Additional information about NHGRI can be found at: https://www.genome.gov.

About the National Institutes of Health (NIH):NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit http://www.nih.gov.

NIHTurning Discovery Into Health

Erin Jimenez, Claire C. Slevin, Wei Song, Zelin Chen, Stephen C. Frederickson, Derek Gildea, Weiwei Wu, Abdel G. Elkahloun, Ivan Ovcharenko, Shawn M. Burgess.A regulatory network of Sox and Six transcription factors initiate a cell fate transformation during hearing regeneration in adult zebrafish. Cell Genomics, 2022.https://doi.org/10.1016/j.xgen.2022.100170.

###

Read more here:
Genomics study identifies unique set of proteins that restores hearing in zebrafish - National Institutes of Health (.gov)

The GlobalCell Expansion Market Size,Report and Forecast 2022-2027 by Expert Market Research gives an extensive outlook of the global cell expansion market, assessing the market on the basis of its segments like product, cell type, application, end-use, and major regions.

Get a Free Sample Report with Table of Contents https://www.expertmarketresearch.com/reports/cell-expansion-market/requestsample

The key highlights of the report include:

Market Overview (2017-2027)

Historical Market Size (2021): USD15.1 billion Forecast CAGR (2022-2027):15% Forecast Market Size (2027): USD35 billion

The global cell expansion market is expected to gain momentum in the upcoming years on account of the upsurge in the utilisation of automated solutions in the applications of cell expansion.

Automated systems reduce the manpower requirements along with costs sustained while the fabrication of gene therapies, cell therapy products, and other biologics that leads to reliable and robust processes. This is further expected to propel the market growth of cell expansion.

The increasing consumption of cell expansion in various industries including hospitals, pharma and biotech companies, research activities, and academics, among others are further expected to fuel the market growth. The surging prevalence of chronic diseases along with the rising emphasis on personalized medicine is boosting the demand for cell expansion in the medical industry.

With an increase in incidences of diseases like cancer and diabetes, there is an increased demand for deep research to build new treatment alternatives. Moreover, there are government initiatives like investments for cell-based research and a growing emphasis on the research and development of cell-based therapies. These initiatives, along with the rising Good Manufacturing Practices certifications for cell therapy production facilities are further likely to bolster the cell expansion market growth during the forecast period.

Cell expansion is a significant cellular procedure for plant growth, which has a net outcome of internal turgor pressure as well as irreversible cell wall extension.

Cell-wall-associated proteins of the expansion family are major components in this procedure. It needs the synthesis of new cell wall material as well as the controlled loosening of the wall to permit it to stretch and rise in the area.

Read Full Report with Table of Contents https://www.expertmarketresearch.com/reports/cell-expansion-market

Based on product, the market is segmented into:

Consumables Reagents, Media, and Serum Disposables Instruments Cell Expansion Supporting Equipment Bioreactors Automated Cell Expansion Systems

By cell type, the cell expansion market is bifurcated into:

Human Cells Animal Cells

On the basis of application, the market is segregated into:

Regenerative Medicine and Stem Cell Research Cancer and Cell-Based Research Others

Based on end use, the market is divided into:

Biotechnology and Biopharmaceutical Companies Research Institutes Cell Banks Others

By region, the market is segmented into:

North America Latin America Asia Pacific Europe Middle East and Africa

The rising employment of cell expansion in the research and development of medicines to treat various diseases is expected to drive cell expansion market growth. Cell expansion is utilized in the production of drugs, therapeutics, antibiotics, and vaccines. With the innovation of products in the growth of cell expansion augmenting the healthcare industry and evolving technology, the market for cell expansion is anticipated to grow during the forecast period.

Based on product, the consumables segment is holding a significant segment in the market share for cell expansion. This is due to the accessibility of a broad variety of commercial media along with reagent products that are devoted to a particular type of cell. The surging production of vaccines along with other biologics in the biotechnology as well as biopharmaceutical industries is driving the consumable segment growth in the market.

Meanwhile, the instrument segment is likely to gain momentum in the cell expansion market growth on account of the automation in bioreactors as well as other expansion platforms to boost the efficiency of culturing processes. The start of automated stages regulates the process as well as enables process tracking, thereby minimizing the hands-on time. This facilitates more effective usage of the time of skilled personnel.

On the basis of end-use, the research institutes segment is expected to drive the market growth. This is on account of the rise in the engagement of researchers in various studies in the biomedical field coupled with augmented funding for regenerative drugs as well as stem cell research.

The major players in the global cell expansion market report are:

The report covers the market shares, capacities, plant turnarounds, expansions, investments and mergers and acquisitions, among other latest developments of these market players.

The report studies the latest updates in the market, along with their impact across the market. It also analysis the market demand, together with its price and demand indicators. The report also tracks the market on the bases of SWOT and Porters Five Forces Models.

Related Reports

High-Speed Motor Market:https://www.expertmarketresearch.com/reports/high-speed-motor-market

Nitric Acid Market: https://www.expertmarketresearch.com/reports/nitric-acid-market

Omega 3 Market: https://www.expertmarketresearch.com/reports/omega-3-market

Sake Market: https://www.expertmarketresearch.com/reports/sake-market

Lithium Ion Battery Companies:https://www.expertmarketresearch.com/articles/top-lithium-ion-battery-companies

About Us:

Expert Market Research (EMR)is leading market research company with clients across the globe. Through comprehensive data collection and skillful analysis and interpretation of data, the company offers its clients extensive, latest, and actionable market intelligence which enables them to make informed and intelligent decisions and strengthen their position in the market. The clientele ranges from Fortune 1000 companies to small and medium scale enterprises.

EMR customises syndicated reports according to clients requirements and expectations. The company is active across over 15 prominent industry domains, including food and beverages, chemicals and materials, technology and media, consumer goods, packaging, agriculture, and pharmaceuticals, among others.

Over3000 EMR consultantsand more than 100 analysts work very hard to ensure that clients get only the most updated, relevant, accurate and actionable industry intelligence so that they may formulate informed, effective and intelligent business strategies and ensure their leadership in the market.

Media Contact:

Company Name: Claight CorporationContact Person: Sophia Grace, Corporate Sales Specialist U.S.A.Email: [emailprotected]Toll Free Number: +1-415-325-5166 | +44-702-402-5790Address: 30 North Gould Street, Sheridan, WY 82801, USAWebsite: http://www.expertmarketresearch.comLinkedIn:-https://www.linkedin.com/company/expert-market-research

Continue reading here:
Global Cell Expansion Market Size to Grow at a CAGR of 15% during the Forecast Period 2022-2027 - Digital Journal

Funding to Advance Novel Treatments and Strengthen MECC's Robust Patient Navigation Program

BRONX, N.Y., Sept. 15, 2022 /PRNewswire/ -- The American Cancer Society (ACS) has awarded Montefiore Einstein Cancer Center (MECC) more than $2.1 million to support cancer research and reduce individual and systematic barriers that prevent people from accessing cancer care.

Edward Chu, M.D., M.M.S., director of the MECC; vice president for cancer medicine at Montefiore Health System; and the Carol and Roger Einiger Professor of Cancer Medicine and professor of medicine, of oncology, and of molecular pharmacology at Albert Einstein College of Medicine

Approximately 40% of people born in the United States will receive a cancer diagnosis. In the Bronxthe nation's poorest urban county where 29.7% of residents live below the poverty lineMECC sees more than 3,500 people with new cancer diagnoses each year. Bronx residents are more likely to be diagnosed at later stages of disease, compared to the national average. This disparity is consistent with other historically marginalized communities and is an area of active research at the cancer center.

Developing New Cancer TreatmentsThe largest ACS grantsfor $792,000 and $660,000support research by Haiying Cheng, M.D., Ph.D., and Kira Gritsman, M.D., Ph.D., respectively. Dr. Cheng, a member of MECC and associate professor of oncology and of medicine at Albert Einstein College of Medicine, focuses on people with lung cancer, the majority of whom develop metastatic disease. She found that a gene called RICTOR is amplified in a group of lung cancer patients who face a high risk that their lung tumors will spread to the brain. With her ACS grant, Dr. Cheng hopes to determine if targeting RICTOR can treat lung cancer metastases or even prevent them from forming.

In studies of blood cancers called myeloproliferative neoplasms (MPNs), Dr. Gritsman, co-leader of MECC's stem cell and cancer biology research program and professor of oncology, of medicine, and of cell biology at Einstein, found that crizotiniba drug approved for treating lung cancerproved effective in a people with a type of MPN. The ACSsupport assists her lab in determining if crizotinib prevents out-of-control blood-cell division in mouse models of MPN, with the goal of moving the drug swiftly into clinical trials. In addition, she will investigate a protein inhibited by crizotinib, RON kinase, as a new target for MPN.

Story continues

Addressing Socioeconomic BarriersThe ACS grants will also enable MECC to add navigators to streamline appointments, such as imaging studies, lab assessments and treatments, for individuals with locally advanced, non-metastatic cancer who would benefit from neoadjuvant therapy (NAT), which is intended to shrink a tumor prior to surgery. This new initiative is particularly important in the Bronx, where only 60% of MECC's patients complete all intended NAT visits and up to 40% miss at least one due to treatment toxicity or socioeconomic factors.

"We pride ourselves on delivering the most research-driven cancer care, but if we don't fully understand and address the social factors that interfere with scheduling and attending appointments, we're never going to reach our ultimate goal healing people so they can return to living their lives," said Edward Chu, M.D., M.M.S., director of the MECC; vice president for cancer medicine at Montefiore Health System; and the Carol and Roger Einiger Professor of Cancer Medicine and professor of medicine, of oncology, and of molecular pharmacology at Albert Einstein College of Medicine. "By deepening our partnership with the ACS, we're advancing our ability to recognize infrastructural biases, identify new treatments relevant to our community and provide the very best support to our patients and their families."

The ACS funding is also helping MECC tackle transportation barriers, which are strongly associated with no-show visits, and is adding more free cancer screenings and continuing education courses for doctors and nurses aimed at improving racial equity.

"As a nationwide leader in cancer education and advocacy, we are proud to partner with Montefiore Einstein Cancer Center to better understand the biology of cancer and how socioeconomic factors impact care access and cancer outcomes," said Connie Bordenga, MD, MS, Cancer Support Strategic Partnerships Manager at the American Cancer Society. "Our work in tackling inequities is only the beginning of a larger shift in how we as a country will redefine the future of cancer care."

About Montefiore Einstein Cancer Center

Montefiore Einstein Cancer Center (MECC) is a national leader in cancer research and care located in the ethnically diverse and economically disadvantaged borough of the Bronx, N.Y. MECC combines the exceptional science of Albert Einstein College of Medicine with the multidisciplinary and team-based approach to cancer care of Montefiore Health System. Founded in 1971 and a National Cancer Institute (NCI)-designated Cancer Center since 1972, MECC is redefining excellence in cancer research, clinical care, education and training, and community outreach and engagement. Its mission is to reduce the burden of cancer for all, especially people from historically marginalized communities.

About the American Cancer Society

The American Cancer Society is on a mission to free the world from cancer. We invest in lifesaving research, provide 24/7 information and support, and work to ensure that individuals in every community have access to cancer prevention, detection, and treatment. For more information, visit cancer.org.

Connie Bordenga, MD, MS, Cancer Support Strategic Partnerships Manager at the American Cancer Society

Cision

View original content to download multimedia:https://www.prnewswire.com/news-releases/the-american-cancer-society-awards-2-1-million-to-montefiore-einstein-cancer-center-to-support-cancer-research-and-tackle-inequities-301625814.html

SOURCE Montefiore Einstein Cancer Center

Go here to read the rest:
The American Cancer Society Awards $2.1 Million to Montefiore Einstein Cancer Center to Support Cancer Research and Tackle Inequities - Yahoo Finance